Nicotinic receptors and stages of nicotine dependence

Journal of Psychopharmacology

Volumn 24, Issue 6, 2010, Pages 793-808

  Brennan, K A ^a   Lea, R A ^a   Fitzmaurice, P S ^a   Truman, P ^a  

^a INSTITUTE OF ENVIRONMENTAL SCIENCE AND RESEARCH   (New Zealand)

Author keywords

Acetylcholine nicotinic receptor; Buproprion; Nicotine; Nicotine replacement therapy; Stages of dependence; Upregulation; Varenicline

Indexed keywords

AMFEBUTAMONE; METHADONE; NICOTINE; NICOTINE GUM; NICOTINIC RECEPTOR; PLACEBO; VARENICLINE;

ADAPTATION; BINDING AFFINITY; CLINICAL TRIAL; CONFORMATIONAL TRANSITION; DEPRESSION; DOPAMINERGIC SYSTEM; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG TARGETING; ELECTROPHYSIOLOGY; HEROIN DEPENDENCE; HUMAN; LOW DRUG DOSE; NEUROMODULATION; NEUROTRANSMISSION; NICOTINE REPLACEMENT THERAPY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; RECEPTOR BINDING; RECEPTOR OCCUPANCY; REVIEW; SIGNAL TRANSDUCTION; SMOKING CESSATION; TOBACCO DEPENDENCE; WITHDRAWAL SYNDROME;

BRAIN; DOPAMINE; HUMANS; NICOTINE; RECEPTORS, NICOTINIC; TOBACCO USE DISORDER; UP-REGULATION;

EID: 77953014487     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881108100256     Document Type: Review

References (194)

1. Ahluwalia, JS, Harris, KJ, Catley, D., Okuyemi, KS, Mayo, MS (2002) Sustained-release bupropion for smoking cessation in African Americans: a randomized controlled trial. Jama 288: 468-474.
2. Algan, O., Furedy, JJ, Demirgoren, S., Vincent, A., Pogun, S. (1997) Effects of tobacco smoking and gender on interhemispheric cognitive function: performance and confidence measures. Behav Pharmacol 8: 416-428.
3. Ascher, JA, Cole, JO, Colin, JN, Feighner, JP, Ferris, RM, Fibiger, HC, et al. (1995) Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry 56: 395-401.
4. Baker, LK, Alexander, JK, Vallejo, YF, Chi, H., Green, WN, Vezina, P. (2005) Nicotine upregulates, VTA nAChRs and requires these receptors to induce locomotor sensitization. Soc Neurosci Abst 31: 1027.
5. Balfour, DJ, Wright, AE, Benwell, ME, Birrell, CE (2000) The putative role of extra-synaptic mesolimbic dopamine in the neurobiology of nicotine dependence. Behav Brain Res 113: 73-83.
6. Benowitz, NL (1988) Drug therapy. Pharmacologic aspects of cigarette smoking and nicotine addition. N Engl J Med 319: 1318-1330.
7. Benwell, ME, Balfour, DJ, Anderson, JM (1988) Evidence that tobacco smoking increases the density of (-)-[3H]nicotine binding sites in human brain. J Neurochem 50: 1243-1247.
8. Berg, DK, Boyd, RT, Halvorsen, SW, Higgins, LS, Jacob, MH, Margiotta, JF (1989) Regulating the number and function of neuronal acetylcholine receptors. Trends Neurosci 12: 16-21.
9. Berridge, KC, Robinson, TE (1998) What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience. Brain Res Brain Res Rev 28: 309-369.
10. Besson, M., David, V., Suarez, S., Cormier, A., Cazala, P., Changeux, JP, et al. (2006) Genetic dissociation of two behaviors associated with nicotine addiction: beta-2 containing nicotinic receptors are involved in nicotine reinforcement but not in withdrawal syndrome. Psychopharmacology (Berl) 187: 189-199.
11. Besson, M., Granon, S., Mameli-Engvall, M., Cloez-Tayarani, I., Maubourguet, N., Cormier, A., et al. (2007) Long-term effects of chronic nicotine exposure on brain nicotinic receptors. Proc Natl Acad Sci U S A 104: 8155-8160.
12. Breese, CR, Marks, MJ, Logel, J., Adams, CE, Sullivan, B., Collins, AC, et al. (1997) Effect of smoking history on [3H]nicotine binding in human postmortem brain. J Pharmacol Exp Ther 282: 7-13.
13. Bruijnzeel, AW, Markou, A. (2004) Adaptations in cholinergic transmission in the ventral tegmental area associated with the affective signs of nicotine withdrawal in rats. Neuropharmacology 47: 572-579.
14. Buisson, B., Bertrand, D. (2001) Chronic exposure to nicotine upregulates the human (alpha)4((beta). nicotinic acetylcholine receptor function. J Neurosci 21: 1819-1829.
15. Buisson, B., Gopalakrishnan, M., Arneric, SP, Sullivan, JP, Bertrand, D. (1996) Human alpha4beta2 neuronal nicotinic acetylcholine receptor in HEK 293 cells: a patch-clamp study. J Neurosci 16: 7880-7891.
16. Cadoni, C., Di Chiara, G. (2000) Differential changes in accumbens shell and core dopamine in behavioral sensitization to nicotine. Eur J Pharmacol 387: R23 - R25.
17. Cahill, K., Stead, LF, Lancaster, T. (2007) Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 1: CD006103.
18. Cassels, BK, Bermudez, I., Dajas, F., Abin-Carriquiry, JA, Wonnacott, S. (2005) From ligand design to therapeutic efficacy: the challenge for nicotinic receptor research. Drug Discov Today 10: 1657-1665.
19. Cepeda-Benito, A. (1993) Meta-analytical review of the efficacy of nicotine chewing gum in smoking treatment programs. J Consult Clin Psychol 61: 822-830.
20. Champtiaux, N., Han, ZY, Bessis, A., Rossi, FM, Zoli, M., Marubio, L., et al. (2002) Distribution and pharmacology of alpha 6-containing nicotinic acetylcholine receptors analyzed with mutant mice. J Neurosci 22: 1208-1217.
21. Charpantier, E., Barneoud, P., Moser, P., Besnard, F., Sgard, F. (1998) Nicotinic acetylcholine subunit mRNA expression in dopaminergic neurons of the rat substantia nigra and ventral tegmental area. Neuroreport 9: 3097-3101.
22. Chavez-Noriega, LE, Crona, JH, Washburn, MS, Urrutia, A., Elliott, KJ, Johnson, EC (1997) Pharmacological characterization of recombinant human neuronal nicotinic acetylcholine receptors h alpha 2 beta 2, h alpha 2 beta 4, h alpha 3 beta 2, h alpha 3 beta 4, h alpha 4 beta 2, h alpha 4 beta 4 and h alpha 7 expressed in Xenopus oocytes. J Pharmacol Exp Ther 280: 346-356.
23. Chiamulera, C., Borgo, C., Falchetto, S., Valerio, E., Tessari, M. (1996) Nicotine reinstatement of nicotine self-administration after long-term extinction. Psychopharmacology (Berl) 127: 102-107.
24. Clarke, PB (1990) Mesolimbic dopamine activation-the key to nicotine reinforcement. Ciba Found Symp 152: 153-162 discussion 162-158.
25. Cooper, BR, Wang, CM, Cox, RF, Norton, R., Shea, V., Ferris, RM (1994) Evidence that the acute behavioral and electrophysiological effects of bupropion (Wellbutrin) are mediated by a noradrenergic mechanism. Neuropsychopharmacology 11: 133-141.
26. Corrigall, WA, Coen, KM (1989) Nicotine maintains robust self-administration in rats on a limited-access schedule. Psychopharmacology (Berl) 99: 473-478.
27. Corrigall, WA, Coen, KM (1991) Selective dopamine antagonists reduce nicotine self-administration. Psychopharmacology (Berl) 104: 171-176.
28. Corrigall, WA, Coen, KM, Adamson, KL (1994) Self-administered nicotine activates the mesolimbic dopamine system through the ventral tegmental area. Brain Res 653: 278-284.
29. Corrigall, WA, Coen, KM, Adamson, KL, Chow, BL, Zhang, J. (2000) Response of nicotine self-administration in the rat to manipulations of mu-opioid and gamma-aminobutyric acid receptors in the ventral tegmental area. Psychopharmacology (Berl) 149: 107-114.
30. Corrigall, WA, Franklin, KB, Coen, KM, Clarke, PB (1992) The mesolimbic dopaminergic system is implicated in the reinforcing effects of nicotine. Psychopharmacology (Berl) 107: 285-289.
31. Corringer, PJ, Le Novere, N., Changeux, JP (2000) Nicotinic receptors at the amino acid level. Annu Rev Pharmacol Toxicol 40: 431-458.
32. Creese, I., Sibley, DR (1981) Receptor adaptations to centrally acting drugs. Annu Rev Pharmacol Toxicol 21: 357-391.
33. Dale, LC, Hurt, RD, Offord, KP, Lawson, GM, Croghan, IT, Schroeder, DR (1995) High-dose nicotine patch therapy. Percentage of replacement and smoking cessation. Jama 274: 1353-1358.
34. Dani, JA (2001) Overview of nicotinic receptors and their roles in the central nervous system. Biol Psychiatry 49: 166-174.
35. Dani, JA, Heinemann, S. (1996) Molecular and cellular aspects of nicotine abuse. Neuron 16: 905-908.
36. Davies, AR, Hardick, DJ, Blagbrough, IS, Potter, BV, Wolstenholme, AJ, Wonnacott, S. (1999) Characterisation of the binding of [3H] methyllycaconitine: a new radioligand for labelling alpha 7-type neuronal nicotinic acetylcholine receptors. Neuropharmacology 38: 679-690.
37. Davila-Garcia, MI, Musachio, JL, Kellar, KJ (2003) Chronic nicotine administration does not increase nicotinic receptors labeled by [125I]epibatidine in adrenal gland, superior cervical ganglia, pineal or retina. J Neurochem 85: 1237-1246.
38. De Luca, V., Wong, AH, Muller, DJ, Wong, GW, Tyndale, RF, Kennedy, JL (2004) Evidence of association between smoking and alpha7 nicotinic receptor subunit gene in schizophrenia patients. Neuropsychopharmacology 29: 1522-1526.
39. Deutch, AY, Holliday, J., Roth, RH, Chun, LL, Hawrot, E. (1987) Immunohistochemical localization of a neuronal nicotinic acetylcholine receptor in mammalian brain. Proc Natl Acad Sci U S A 84: 8697-8701.
40. Deutschlander, A., Stephan, T., Riedel, E., Zingler, VC, Hufner, K., Wiesmann, M., et al. (2008) Nicotine-induced nystagmus correlates with midpontine activation. Neuroimage 41: 479-482.
41. Di Chiara, G. (2000) Role of dopamine in the behavioural actions of nicotine related to addiction. Eur J Pharmacol 393: 295-314.
42. Di Chiara, G., Imperato, A. (1988) Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci U S A 85: 5274-5278.
43. Di Matteo, V., Pierucci, M., Di Giovanni, G., Benigno, A., Esposito, E. (2007) The neurobiological bases for the pharmacotherapy of nicotine addiction. Curr Pharm Des 13: 1269-1284.
44. DiFranza, JR, Savageau, JA, Fletcher, K., Pbert, L., OLoughlin, J., McNeill, AD, et al. (2007) Susceptibility to nicotine dependence: the Development and Assessment of Nicotine Dependence in Youth 2 study. Pediatrics 120: e974 - e983.
45. Doggrell, SA (2007) Which is the best primary medication for long-term smoking cessation-nicotine replacement therapy, bupropion or varenicline. Expert Opin Pharmacother 8: 2903-2915.
46. Epping-Jordan, MP, Picciotto, MR, Changeux, JP, Pich, EM (1999) Assessment of nicotinic acetylcholine receptor subunit contributions to nicotine self-administration in mutant mice. Psychopharmacology (Berl) 147: 25-26.
47. Etter, JF (2006) Cytisine for smoking cessation: a literature review and a meta-analysis. Arch Intern Med 166: 1553-1559.
48. Fagen, ZM, Mitchum, R., Vezina, P., McGehee, DS (2007) Enhanced nicotinic receptor function and drug abuse vulnerability. J Neurosci 27: 8771-8778.
49. Fasanmade, AA, Oyebola, DD (1993) Effects of adrenoceptor blockers on the cardiorespiratory response to nicotine in rats. Afr J Med Med Sci 22: 81-87.
50. Fenster, CP, Whitworth, TL, Sheffield, EB, Quick, MW, Lester, RA (1999) Upregulation of surface alpha4beta2 nicotinic receptors is initiated by receptor desensitization after chronic exposure to nicotine. J Neurosci 19: 4804-4814.
51. Fiellin, DA, Friedland, GH, Gourevitch, MN (2006) Opioid dependence: rationale for and efficacy of existing and new treatments. Clin Infect Dis 43 (Suppl. 4). S173 - S177.
52. Fiore, MC (2000) Treating tobacco use and dependence: an introduction to the US Public Health Service Clinical Practice Guideline. Respir Care 45: 1196-1199.
53. Fiore, MC, Smith, SS, Jorenby, DE, Baker, TB (1994) The effectiveness of the nicotine patch for smoking cessation. A meta-analysis. Jama 271: 1940-1947.
54. Fiorino, DF, Coury, A., Fibiger, HC, Phillips, AG (1993) Electrical stimulation of reward sites in the ventral tegmental area increases dopamine transmission in the nucleus accumbens of the rat. Behav Brain Res 55: 131-141.
55. Flores, CM, Davila-Garcia, MI, Ulrich, YM, Kellar, KJ (1997) Differential regulation of neuronal nicotinic receptor binding sites following chronic nicotine administration. J Neurochem 69: 2216-2219.
56. Foley, KF, DeSanty, KP, Kast, RE (2006) Bupropion: pharmacology and therapeutic applications. Expert Rev Neurother 6: 1249-1265.
57. Ford, CL, Zlabek, JA (2005) Nicotine replacement therapy and cardiovascular disease. Mayo Clin Proc 80: 652-656.
58. Foulds, J., Stapleton, JA, Bell, N., Swettenham, J., Jarvis, MJ, Russell, MA (1997) Mood and physiological effects of subcutaneous nicotine in smokers and never-smokers. Drug Alcohol Depend 44: 105-115.
59. French, ED, Dillon, K., Ali, SF (1996) Effects of ibogaine, and cocaine and morphine after ibogaine, on ventral tegmental dopamine neurons. Life Sci 59: PL199 - PL205.
60. Frishman, WH (2007) Smoking cessation pharmacotherapy-nicotine and non-nicotine preparations. Prev Cardiol 10 (2 Suppl. 1). 10-22.
61. Fryer, JD, Lukas, RJ (1999) Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine. J Pharmacol Exp Ther 288: 88-92.
62. George, TP, Verrico, CD, Picciotto, MR, Roth, RH (2000) Nicotinic modulation of mesoprefrontal dopamine neurons: pharmacologic and neuroanatomic characterization. J Pharmacol Exp Ther 295: 58-66.
63. Girod, R., Barazangi, N., McGehee, D., Role, LW (2000) Facilitation of glutamatergic neurotransmission by presynaptic nicotinic acetylcholine receptors. Neuropharmacology 39: 2715-2725.
64. Golan, DE, Tashjian, AH, Armstrong, EJ, Armstrong, AW (2008) Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. United States Lippincott Williams and Wilkins.
65. Goldberg, SR, Spealman, RD (1982) Maintenance and suppression of behavior by intravenous nicotine injections in squirrel monkeys. Fed Proc 41: 216-220.
66. Goldberg, SR, Spealman, RD, Goldberg, DM (1981) Persistent behavior at high rates maintained by intravenous self-administration of nicotine. Science 214: 573-575.
67. Gonzales, D., Rennard, SI, Nides, M., Oncken, C., Azoulay, S., Billing, CB, et al. (2006) Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. Jama 296: 47-55.
68. Grenhoff, J., Svensson, TH (1989) Pharmacology of nicotine. Br J Addict 84: 477-492.
69. Griesar, WS, Zajdel, DP, Oken, BS (2002) Nicotine effects on alertness and spatial attention in non-smokers. Nicotine Tob Res 4: 185-194.
70. Grottick, AJ, Trube, G., Corrigall, WA, Huwyler, J., Malherbe, P., Wyler, R., et al. (2000) Evidence that nicotinic alpha(7) receptors are not involved in the hyperlocomotor and rewarding effects of nicotine. J Pharmacol Exp Ther 294: 1112-1119.
71. Haertzen, CA, Kocher, TR, Miyasato, K. (1983) Reinforcements from the first drug experience can predict later drug habits and/or addiction: results with coffee, cigarettes, alcohol, barbiturates, minor and major tranquilizers, stimulants, marijuana, hallucinogens, heroin, opiates and cocaine. Drug Alcohol Depend 11: 147-165.
72. Hayford, KE, Patten, CA, Rummans, TA, Schroeder, DR, Offord, KP, Croghan, IT, et al. (1999) Efficacy of bupropion for smoking cessation in smokers with a former history of major depression or alcoholism. Br J Psychiatry 174: 173-178.
73. Heatherton, TF, Kozlowski, LT, Frecker, RC, Fagerstrom, KO (1991) The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br J Addict 86: 1119-1127.
74. Hildebrand, BE, Nomikos, GG, Bondjers, C., Nisell, M., Svensson, TH (1997) Behavioral manifestations of the nicotine abstinence syndrome in the rat: peripheral versus central mechanisms. Psychopharmacology (Berl) 129: 348-356.
75. Hildebrand, BE, Panagis, G., Svensson, TH, Nomikos, GG (1999) Behavioral and biochemical manifestations of mecamylamine-precipitated nicotine withdrawal in the rat: role of nicotinic receptors in the ventral tegmental area. Neuropsychopharmacology 21: 560-574.
76. Hooks, MS, Juncos, JL, Justice Jr, JB, Meiergerd, SM, Povlock, SL, Schenk, JO, et al. (1994) Individual locomotor response to novelty predicts selective alterations in D1 and D2 receptors and mRNAs. J Neurosci 14: 6144-6152.
77. Hughes, JR (2007) Effects of abstinence from tobacco: etiology, animal models, epidemiology, and significance: a subjective review. Nicotine Tob Res 9: 329-339.
78. Hughes, JR, Stead, LF, Lancaster, T. (2006) Antidepressants for Smoking Cessation: The Cochrane Database of Systemic Reviews. Chichester, UK: John Wiley & Sons Ltd. http://www.mrw.interscience.wiley.com/cochrane/clsysrev/ articles/CD000031/pdf-fs.s.html (accessed 10.09.08).
79. Hurt, RD, Sachs, DP, Glover, ED, Offord, KP, Johnston, JA, Dale, LC, et al. (1997) A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 337: 1195-1202.
80. Hutchison, KE, Allen, DL, Filbey, FM, Jepson, C., Lerman, C., Benowitz, NL, et al. (2007) CHRNA4 and tobacco dependence: from gene regulation to treatment outcome. Arch Gen Psychiatry 64: 1078-1086.
81. Imperato, A., Mulas, A., Di Chiara, G. (1986) Nicotine preferentially stimulates dopamine release in the limbic system of freely moving rats. Eur J Pharmacol 132: 337-338.
82. Johnson, PM, Hollander, JA, Kenny, PJ (2008) Decreased brain reward function during nicotine withdrawal in C57BL6 mice: evidence from intracranial self-stimulation (ICSS) studies. Pharmacol Biochem Behav 90: 409-415.
83. Jones, IW, Wonnacott, S. (2004) Precise localization of alpha7 nicotinic acetylcholine receptors on glutamatergic axon terminals in the rat ventral tegmental area. J Neurosci 24: 11244-11252.
84. Jorenby, DE, Hays, JT, Rigotti, NA, Azoulay, S., Watsky, EJ, Williams, KE, et al. (2006) Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. Jama 296: 56-63.
85. Jorenby, DE, Leischow, SJ, Nides, MA, Rennard, SI, Johnston, JA, Hughes, AR, et al. (1999) A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 340: 685-691.
86. Jorenby, DE, Smith, SS, Fiore, MC, Hurt, RD, Offord, KP, Croghan, IT, et al. (1995) Varying nicotine patch dose and type of smoking cessation counseling. Jama 274: 1347-1352.
87. Kalivas, PW (1993) Neurotransmitter regulation of dopamine neurons in the ventral tegmental area. Brain Res Brain Res Rev 18: 75-113.
88. Kaufmann, V., Jepson, C., Rukstalis, M., Perkins, K., Audrain-McGovern, J., Lerman, C. (2004) Subjective effects of an initial dose of nicotine nasal spray predict treatment outcome. Psychopharmacology (Berl) 172: 271-276.
89. Killen, JD, Robinson, TN, Haydel, KF, Hayward, C., Wilson, DM, Hammer, LD, et al. (1997) Prospective study of risk factors for the initiation of cigarette smoking. J Consult Clin Psychol 65: 1011-1016.
90. Kleykamp, BA, Jennings, JM, Blank, MD, Eissenberg, T. (2005) The effects of nicotine on attention and working memory in never-smokers. Psychol Addict Behav 19: 433-438.
91. Klink, R. de Kerchove d,Exaerde, A., Zoli, M., Changeux, JP (2001) Molecular and physiological diversity of nicotinic acetylcholine receptors in the midbrain dopaminergic nuclei. J Neurosci 21: 1452-1463.
92. Koob, GF, Le Moal, M. (1997) Drug abuse: hedonic homeostatic dysregulation. Science 278: 52-58.
93. Lai, A., Parameswaran, N., Khwaja, M., Whiteaker, P., Lindstrom, JM, Fan, H., et al. (2005) Long-term nicotine treatment decreases striatal alpha 6* nicotinic acetylcholine receptor sites and function in mice. Mol Pharmacol 67: 1639-1647.
94. Lambert, NM, McLeod, M., Schenk, S. (2006) Subjective responses to initial experience with cocaine: an exploration of the incentive-sensitization theory of drug abuse. Addiction 101: 713-725.
95. Laviolette, SR, van der Kooy, D. (2003) Blockade of mesolimbic dopamine transmission dramatically increases sensitivity to the rewarding effects of nicotine in the ventral tegmental area. Mol Psychiatry 8: 50-59.
96. Laviolette, SR, van der Kooy, D. (2004) The neurobiology of nicotine addiction: bridging the gap from molecules to behaviour. Nat Rev Neurosci 5: 55-65.
97. Lena, C., Changeux, JP (1997) Pathological mutations of nicotinic receptors and nicotine-based therapies for brain disorders. Curr Opin Neurobiol 7: 674-682.
98. Levin, ED, McClernon, FJ, Rezvani, AH (2006) Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification, and anatomic localization. Psychopharmacology (Berl) 184: 523-539.
99. Lerman, CE, Schnoll, RA, Munafo, MR (2007) Genetics and smoking cessation improving outcomes in smokers at risk. Am J Prev Med 33: S398 - S405.
100. Lippiello, PM, Sears, SB, Fernandes, KG (1987) Kinetics and mechanism of L-[3H]nicotine binding to putative high affinity receptor sites in rat brain. Mol Pharmacol 31: 392-400.
101. Liu, Q., Li, Z., Ding, JH, Liu, SY, Wu, J., Hu, G. (2006) Iptakalim inhibits nicotine-induced enhancement of extracellular dopamine and glutamate levels in the nucleus accumbens of rats. Brain Res 1085: 138-143. (Pubitemid 43728191)
102. Lopez, AD, Mathers, CD, Ezzati, M., Jamison, DT, Murray, CJL (2006) Global Burden of Disease and Risk Factors. Washington: The World Bank.
103. Lowinson, JH, Ruiz, P., Millman, RB, Langrad, JG (2005) Substance Abuse: A Comprehensive Textbook. United States Lippincott Williams & Wilkins.
104. Lukas, RJ, Changeux, JP, Le Novere, N., Albuquerque, EX, Balfour, DJ, Berg, DK, et al. (1999) International Union of Pharmacology. XX. Current status of the nomenclature for nicotinic acetylcholine receptors and their subunits. Pharmacol Rev 51: 397-401.
105. Malin, DH, Lake, JR, Carter, VA, Cunningham, JS, Hebert, KM, Conrad, DL, et al. (1994) The nicotinic antagonist mecamylamine precipitates nicotine abstinence syndrome in the rat. Psychopharmacology (Berl) 115: 180-184.
106. Malin, DH, Lake, JR, Upchurch, TP, Shenoi, M., Rajan, N., Schweinle, WE (1998) Nicotine abstinence syndrome precipitated by the competitive nicotinic antagonist dihydro-beta-erythroidine. Pharmacol Biochem Behav 60: 609-613.
107. Mansvelder, HD, Fagen, ZM, Chang, B., Mitchum, R., McGehee, DS (2007) Bupropion inhibits the cellular effects of nicotine in the ventral tegmental area. Biochem Pharmacol 74: 1283-1291.
108. Mansvelder, HD, Keath, JR, McGehee, DS (2002) Synaptic mechanisms underlie nicotine-induced excitability of brain reward areas. Neuron 33: 905-919.
109. Mansvelder, HD, McGehee, DS (2000) Long-term potentiation of excitatory inputs to brain reward areas by nicotine. Neuron 27: 349-357.
110. Marks, MJ, Rowell, PP, Cao, JZ, Grady, SR, McCallum, SE, Collins, AC (2004) Subsets of acetylcholine-stimulated 86Rb+ efflux and [125I]-epibatidine binding sites in C57BL/6 mouse brain are differentially affected by chronic nicotine treatment. Neuropharmacology 46: 1141-1157.
111. Marks, MJ, Stitzel, JA, Collins, AC (1985) Time course study of the effects of chronic nicotine infusion on drug response and brain receptors. J Pharmacol Exp Ther 235: 619-628.
112. Martin, BR, Aceto, MD (1981) Nicotine binding sites and their localization in the central nervous system. Neurosci Biobehav Rev 5: 473-478.
113. Marubio, LM, Gardier, AM, Durier, S., David, D., Klink, R., Arroyo-Jimenez, MM, et al. (2003) Effects of nicotine in the dopaminergic system of mice lacking the alpha4 subunit of neuronal nicotinic acetylcholine receptors. Eur J Neurosci 17: 1329-1337.
114. Maskos, U., Molles, BE, Pons, S., Besson, M., Guiard, BP, Guilloux, JP, et al. (2005) Nicotine reinforcement and cognition restored by targeted expression of nicotinic receptors. Nature 436: 103-107.
115. Mathieu-Kia, AM, Kellogg, SH, Butelman, ER, Kreek, MJ (2002) Nicotine addiction: insights from recent animal studies. Psychopharmacology (Berl) 162: 102-118.
116. McCallum, SE, Collins, AC, Paylor, R., Marks, MJ (2006 a) Deletion of the beta 2 nicotinic acetylcholine receptor subunit alters development of tolerance to nicotine and eliminates receptor upregulation. Psychopharmacology (Berl) 184: 314-327.
117. McCallum, SE, Parameswaran, N., Bordia, T., Fan, H., Tyndale, RF, Langston, JW, et al. (2006 b) Increases in alpha4* but not alpha3*/alpha6* nicotinic receptor sites and function in the primate striatum following chronic oral nicotine treatment. J Neurochem 96: 1028-1041.
118. McGehee, DS, Heath, MJ, Gelber, S., Devay, P., Role, LW (1995) Nicotine enhancement of fast excitatory synaptic transmission in CNS by presynaptic receptors. Science 269: 1692-1696.
119. Mehta, MC, Jain, AC, Mehta, A., Billie, M. (1997) Cardiac arrhythmias following intravenous nicotine: experimental study in dogs. J Cardiovasc Pharmacol Ther 2: 291-298. (Pubitemid 27469369)
120. Mihailescu, S., Drucker-Colin, R. (2000) Nicotine, brain nicotinic receptors, and neuropsychiatric disorders. Arch Med Res 31: 131-144.
121. Museo, E., Wise, RA (1994) Place preference conditioning with ventral tegmental injections of cytisine. Life Sci 55: 1179-1186. (Pubitemid 24290421)
122. Nguyen, HN, Rasmussen, BA, Perry, DC (2003) Subtype-selective upregulation by chronic nicotine of high-affinity nicotinic receptors in rat brain demonstrated by receptor autoradiography. J Pharmacol Exp Ther 307: 1090-1097.
123. Nisell, M., Nomikos, GG, Svensson, TH (1994) Systemic nicotine-induced dopamine release in the rat nucleus accumbens is regulated by nicotinic receptors in the ventral tegmental area. Synapse 16: 36-44. (Pubitemid 24013237)
124. Nordberg, A., Romanelli, L., Sundwall, A., Bianchi, C., Beani, L. (1989) Effect of acute and subchronic nicotine treatment on cortical acetylcholine release and on nicotinic receptors in rats and guinea-pigs. Br J Pharmacol 98: 71-78.
125. Ochoa, EL, Chattopadhyay, A., McNamee, MG (1989) Desensitization of the nicotinic acetylcholine receptor: molecular mechanisms and effect of modulators. Cell Mol Neurobiol 9: 141-178.
126. Okamoto, M., Kita, T., Okuda, H., Nakashima, T. (1992) Tolerance to the convulsions induced by daily nicotine treatment in rats. Jpn J Pharmacol 59: 449-455.
127. Olds, J., Milner, P. (1954) Positive reinforcement produced by electrical stimulation of septal area and other regions of rat brain. J Comp Physiol Psychol 47: 419-427.
128. Overstreet, DH, Yamamura, HI (1979) Receptor alterations and drug tolerance. Life Sci 25: 1865-1877.
129. Page, F., Coleman, G., Conduit, R. (2006) The effect of transdermal nicotine patches on sleep and dreams. Physiol Behav 88: 425-432.
130. Paoletti, P., Fornai, E., Maggiorelli, F., Puntoni, R., Viegi, G., Carrozzi, L., et al. (1996) Importance of baseline cotinine plasma values in smoking cessation: results from a double-blind study with nicotine patch. Eur Respir J 9: 643-651.
131. Parker, SL, Fu, Y., McAllen, K., Luo, J., McIntosh, JM, Lindstrom, JM, et al. (2004) Up-regulation of brain nicotinic acetylcholine receptors in the rat during long-term self-administration of nicotine: disproportionate increase of the alpha6 subunit. Mol Pharmacol 65: 611-622.
132. Perkins, KA, Epstein, LH, Stiller, RL, Sexton, JE, Debski, TD, Jacob, RG (1990) Behavioral performance effects of nicotine in smokers and nonsmokers. Pharmacol Biochem Behav 37: 11-15.
133. Perry, DC, Davila-Garcia, MI, Stockmeier, CA, Kellar, KJ (1999) Increased nicotinic receptors in brains from smokers: membrane binding and autoradiography studies. J Pharmacol Exp Ther 289: 1545-1552.
134. Perry, DC, Mao, D., Gold, AB, McIntosh, JM, Pezzullo, JC, Kellar, KJ (2007) Chronic nicotine differentially regulates alpha6- and beta3-containing nicotinic cholinergic receptors in rat brain. J Pharmacol Exp Ther 322: 306-315.
135. Phillips, PE, Stuber, GD, Heien, ML, Wightman, RM, Carelli, RM (2003) Subsecond dopamine release promotes cocaine seeking. Nature 422: 614-618.
136. Piazza, PV, Deminiere, JM, Le Moal, M., Simon, H. (1989) Factors that predict individual vulnerability to amphetamine self-administration. Science 245: 1511-1513.
137. Picciotto, MR, Zoli, M., Rimondini, R., Lena, C., Marubio, LM, Pich, EM, et al. (1998) Acetylcholine receptors containing the beta2 subunit are involved in the reinforcing properties of nicotine. Nature 391: 173-177.
138. Pidoplichko, VI, DeBiasi, M., Williams, JT, Dani, JA (1997) Nicotine activates and desensitizes midbrain dopamine neurons. Nature 390: 401-404.
139. Quick, MW, Lester, RA (2002) Desensitization of neuronal nicotinic receptors. J Neurobiol 53: 457-478.
140. Quik, M. (2004) Smoking, nicotine and Parkinson,s disease. Trends Neurosci 27: 561-568.
141. Reid, MS, Ho, LB, Berger, SP (1998) Behavioral and neurochemical components of nicotine sensitization following 15-day pretreatment: studies on contextual conditioning. Behav Pharmacol 9: 137-148.
142. Rigotti, NA (2002) Clinical practice. Treatment of tobacco use and dependence. N Engl J Med 346: 506-512.
143. Risner, ME, Goldberg, SR (1983) A comparison of nicotine and cocaine self-administration in the dog: fixed-ratio and progressive-ratio schedules of intravenous drug infusion. J Pharmacol Exp Ther 224: 319-326.
144. Robinson, TE, Berridge, KC (2001) Incentive-sensitization and addiction. Addiction 96: 103-114.
145. Rollema, H., Chambers, LK, Coe, JW, Glowa, J., Hurst, RS, Lebel, LA, et al. (2007) Pharmacological profile of the alpha(4)beta(2) nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. Neuropharmacology 52: 985-994.
146. Romach, MK, Glue, P., Kampman, K., Kaplan, HL, Somer, GR, Poole, S., et al. (1999) Attenuation of the euphoric effects of cocaine by the dopamine D1/D5 antagonist ecopipam (SCH 39166). Arch Gen Psychiatry 56: 1101-1106.
147. Rose, JE (2006) Nicotine and nonnicotine factors in cigarette addiction. Psychopharmacology (Berl) 184: 274-285.
148. Rossi, S., Singer, S., Shearman, E., Sershen, H., Lajtha, A. (2005) The effects of cholinergic and dopaminergic antagonists on nicotine-induced cerebral neurotransmitter changes. Neurochem Res 30: 541-558.
149. Sacco, KA, Bannon, KL, George, TP (2004) Nicotinic receptor mechanisms and cognition in normal states and neuropsychiatric disorders. J Psychopharmacol 18: 457-474.
150. Sanderson, EM, Drasdo, AL, McCrea, K., Wonnacott, S. (1993) Upregulation of nicotinic receptors following continuous infusion of nicotine is brain-region-specific. Brain Res 617: 349-352.
151. Schilstrom, B., Fagerquist, MV, Zhang, X., Hertel, P., Panagis, G., Nomikos, GG, et al. (2000) Putative role of presynaptic alpha7* nicotinic receptors in nicotine stimulated increases of extracellular levels of glutamate and aspartate in the ventral tegmental area. Synapse 38: 375-383.
152. Schilstrom, B., Svensson, HM, Svensson, TH, Nomikos, GG (1998) Nicotine and food induced dopamine release in the nucleus accumbens of the rat: putative role of alpha7 nicotinic receptors in the ventral tegmental area. Neuroscience 85: 1005-1009. (Pubitemid 28293408)
153. Schwartz, AG, Prysak, GM, Bock, CH, Cote, ML (2007) The molecular epidemiology of lung cancer. Carcinogenesis 28: 507-518.
154. Schwartz, RD, Kellar, KJ (1985) In vivo regulation of [3H]acetylcholine recognition sites in brain by nicotinic cholinergic drugs. J Neurochem 45: 427-433.
155. Shaham, Y., Adamson, LK, Grocki, S., Corrigall, WA (1997) Reinstatement and spontaneous recovery of nicotine seeking in rats. Psychopharmacology (Berl) 130: 396-403.
156. Sherer, MA, Kumor, KM, Jaffe, JH (1989) Effects of intravenous cocaine are partially attenuated by haloperidol. Psychiatry Res 27: 117-125.
157. Shim, I., Javaid, JI, Wirtshafter, D., Jang, SY, Shin, KH, Lee, HJ, et al. (2001) Nicotine-induced behavioral sensitization is associated with extracellular dopamine release and expression of c-Fos in the striatum and nucleus accumbens of the rat. Behav Brain Res 121: 137-147.
158. Silagy, C., Lancaster, T., Stead, L., Mant, D., Fowler, G. (2006) Nicotine Replacement Therapy for Smoking Cessation: The Cochrane Database of Systemic Reviews. Chichester, UK: John Wiley & Sons. http://www.mrw. interscience.wiley.com/cochrane/clsysrev/articles/CD000146/pdf-fs.html (accessed 10.09.08).
159. Slater, YE, Houlihan, LM, Maskell, PD, Exley, R., Bermudez, I., Lukas, RJ, et al. (2003) Halogenated cytisine derivatives as agonists at human neuronal nicotinic acetylcholine receptor subtypes. Neuropharmacology 44: 503-515.
160. Slemmer, JE, Martin, BR, Damaj, MI (2000) Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther 295: 321-327.
161. Soria, R., Stapleton, JM, Gilson, SF, Sampson-Cone, A., Henningfield, JE, London, ED (1996) Subjective and cardiovascular effects of intravenous nicotine in smokers and non-smokers. Psychopharmacology (Berl) 128: 221-226.
162. Stack, NM (2007) Smoking cessation: an overview of treatment options with a focus on varenicline. Pharmacotherapy 27: 1550-1557.
163. Staley, JK, Krishnan-Sarin, S., Cosgrove, KP, Krantzler, E., Frohlich, E., Perry, E., et al. (2006) Human tobacco smokers in early abstinence have higher levels of beta2* nicotinic acetylcholine receptors than nonsmokers. J Neurosci 26: 8707-8714.
164. Stapleton, JA, Russell, MA, Feyerabend, C., Wiseman, SM, Gustavsson, G., Sawe, U., et al. (1995) Dose effects and predictors of outcome in a randomized trial of transdermal nicotine patches in general practice. Addiction 90: 31-42.
165. Stapleton, JA, Watson, L., Spirling, LI, Smith, R., Milbrandt, A., Ratcliffe, M., et al. (2007) Varenicline in the routine treatment of tobacco dependence: a pre-post comparison with nicotine replacement therapy and an evaluation in those with mental illness. Addiction 103: 146-154.
166. Stead, LF, Perera, R., Bullen, C., Mant, D., Lancaster, T. (2008) Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev (1). CD000146.
167. Steinbach, JH, Ifune, C. (1989) How many kinds of nicotinic acetylcholine receptor are there. Trends Neurosci 12: 3-6.
168. Stolerman, IP, Shoaib, M. (1991) The neurobiology of tobacco addiction. Trends Pharmacol Sci 12: 467-473.
169. Suto, N., Austin, JD, Vezina, P. (2001) Locomotor response to novelty predicts a rat,s propensity to self-administer nicotine. Psychopharmacology (Berl) 158: 175-180.
170. Sziraki, I., Sershen, H., Benuck, M., Lipovac, M., Hashim, A., Cooper, TB, et al. (1999) The effect of cotinine on nicotine- and cocaine-induced
171. Tang, JL, Law, M., Wald, N. (1994) How effective is nicotine replacement therapy in helping people to stop smoking. Bmj 308: 21-26.
172. Tashkin, D., Kanner, R., Bailey, W., Buist, S., Anderson, P., Nides, M., et al. (2001) Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial. Lancet 357: 1571-1575.
173. Tiffany, ST, Drobes, DJ (1991) The development and initial validation of a questionnaire on smoking urges. Br J Addict 86: 1467-1476.
174. Tonnesen, P., Tonstad, S., Hjalmarson, A., Lebargy, F., Van Spiegel, PI, Hider, A., et al. (2003) A multicentre, randomized, double-blind, placebo-controlled, 1-year study of bupropion SR for smoking cessation. J Intern Med 254: 184-192.
175. Tonstad, S. (2006) Smoking cessation efficacy and safety of varenicline, an alpha4beta2 nicotinic receptor partial agonist. J Cardiovasc Nurs 21: 433-436.
176. Vallejo, YF, Buisson, B., Bertrand, D., Green, WN (2005) Chronic nicotine exposure upregulates nicotinic receptors by a novel mechanism. J Neurosci 25: 5563-5572.
177. Voineskos, S., De Luca, V., Mensah, A., Vincent, JB, Potapova, N., Kennedy, JL (2007) Association of alpha4beta2 nicotinic receptor and heavy smoking in schizophrenia. J Psychiatry Neurosci 32: 412-416.
178. Walton, R., Johnstone, E., Munafo, M., Neville, M., Griffiths, S. (2001) Genetic clues to the molecular basis of tobacco addiction and progress towards personalized therapy. Trends Mol Med 7: 70-76.
179. Warner, C., Shoaib, M. (2005) How does bupropion work as a smoking cessation aid. Addict Biol 10: 219-231.
180. Watkins, SS, Epping-Jordan, MP, Koob, GF, Markou, A. (1999) Blockade of nicotine self-administration with nicotinic antagonists in rats. Pharmacol Biochem Behav 62: 743-751.
181. Watkins, SS, Koob, GF, Markou, A. (2000) Neural mechanisms underlying nicotine addiction: acute positive reinforcement and withdrawal. Nicotine Tob Res 2: 19-37.
182. Welton, NJ, Johnstone, EC, David, SP, Munafo, MR (2008) A cost-effectiveness analysis of genetic testing of the DRD2 Taq1A polymorphism to aid treatment choice for smoking cessation. Nicotine Tob Res 10: 231-240.
183. West, R. (1992) Nicotine addiction: a re-analysis of the arguments. Psychopharmacology (Berl) 108: 408-410 discussion 411-406.
184. West, R., Baker, CL, Cappelleri, JC, Bushmakin, AG (2008) Effect of varenicline and bupropion SR on craving, nicotine withdrawal symptoms, and rewarding effects of smoking during a quit attempt. Psychopharmacology (Berl) 197: 371-377.
185. West, R., Hack, S. (1991) Effect of cigarettes on memory search and subjective ratings. Pharmacol Biochem Behav 38: 281-286.
186. WHO (2007) World Health Organisation tobacco information. http://www.whoint/tobacco/en/atlas8pdf (accessed 10.09.08).
187. Wonnacott, S. (1990) The paradox of nicotinic acetylcholine receptor upregulation by nicotine. Trends Pharmacol Sci 11: 216-219.
188. Wonnacott, S., Barik, J. (2007) Nicotinic ACh Receptors. Tocris Bioscience Scientific Review Series 28. http://opus.bath.ac.uk/view/person-id/ 117.html (accessed 12/12/08).
189. Wullner, U., Gundisch, D., Herzog, H., Minnerop, M., Joe, A., Warnecke, M., et al. (2008) Smoking upregulates alpha4beta2* nicotinic acetylcholine receptors in the human brain. Neurosci Lett 430: 34-37.
190. Yates, SL, Bencherif, M., Fluhler, EN, Lippiello, PM (1995) Upregulation of nicotinic acetylcholine receptors following chronic exposure of rats to mainstream cigarette smoke or alpha 4 beta 2 receptors to nicotine. Biochem Pharmacol 50: 2001-2008.
191. Yin, R., French, ED (2000) A comparison of the effects of nicotine on dopamine and non-dopamine neurons in the rat ventral tegmental area: an in vitro electrophysiological study. Brain Res Bull 51: 507-514.
192. Zhu, PJ, Chiappinelli, VA (1999) Nicotine modulates evoked GABAergic transmission in the brain. J Neurophysiol 82: 3041-3045.
193. Zingler, VC, Denecke, K., Jahn, K., von Meyer, L., Krafczyk, S., Krams, M., et al. (2007) The effect of nicotine on perceptual, ocular motor, postural, and vegetative functions at rest and in motion. J Neurol 254: 1689-1697.
194. Zoli, M., Moretti, M., Zanardi, A., McIntosh, JM, Clementi, F., Gotti, C. (2002) Identification of the nicotinic receptor subtypes expressed on dopaminergic terminals in the rat striatum. J Neurosci 22: 8785-8789.